AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 November press release. It is the first asset licensed by the British big ...
an area of therapeutics development that is viewed as being at the forefront of extending the role of cell therapy beyond cancer. As their name suggests, Treg cells play a key role in controlling ...
Gdańsk, Poland – 16 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today ...